Login / Signup
Risankizumab vs. adalimumab for moderate-to-severe plaque psoriasis: a critical appraisal.
Ali Al-Janabi
Richard Bruce Warren
Published in:
The British journal of dermatology (2020)
Keyphrases
</>
rheumatoid arthritis
high intensity
coronary artery disease
juvenile idiopathic arthritis
early onset
ulcerative colitis
hidradenitis suppurativa
drug induced
systemic lupus erythematosus